MESA LABORATORIES INC /CO Form 8-K October 31, 2014

## **UNITED STATES**

#### SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

## **CURRENT REPORT**

## Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

October 31, 2014 Date of Report (Date of earliest event reported)

## MESA LABORATORIES, INC.

(Exact name of registrant as specified in its charter)

Commission File Number: 0-11740

COLORADO84-0872291(State or other jurisdiction of<br/>incorporation)(I.R.S. Employer<br/>Identification No.)

#### **12100 WEST SIXTH AVENUE,**

<u>80228</u> (Zip Code)

## LAKEWOOD, COLORADO

1

(Address of principal executive offices)

Registrant's telephone number, including area code: (303) 987-8000

#### Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

L Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

L Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

|\_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

|\_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

# **ITEM 8.01 OTHER EVENTS**

On October 31, 2014, Amilabo SAS ("Amilabo"), a wholly owned subsidiary of Mesa Laboratories, Inc. (the "Company"), entered into and closed an asset purchase agreement (the "Agreement") with ATI Atlas, Limited ("ATI") whereby it acquired substantially all of the assets (other than cash and accounts receivable) and certain liabilities of ATI. ATI is located near London and is a distributor of the Company's biological indicator products.

# **ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS**

(d) Exhibits:

99.1 Press release dated October 31, 2014.

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DATE: October 31, 2014

Mesa Laboratories, Inc.

(Registrant)

/s/ John J. Sullivan, BY: John J. Sullivan, President and Chief Executive Officer